Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PaxMedicaPXMD Equity-to-Asset is -2.36 as of Sep. 2024.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PaxMedica's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-1.93 Mil. PaxMedica's Total Assets for the quarter that ended in Sep. 2024 was $0.82 Mil.
The historical rank and industry rank for PaxMedica's Equity-to-Asset or its related term are showing as below:
PXMD's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PaxMedica Equity-to-Asset Related Terms
PaxMedica Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for PaxMedica's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PXMD vs BTAX, NBIO, ARTHQ: Equity-to-Asset Comparison
For the Biotechnology subindustry, PaxMedica's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PaxMedica Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PaxMedica's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PaxMedica's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PaxMedica's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PaxMedica (PXMD) has a Equity-to-Asset of -2.36 as of Sep. 2024. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PaxMedica and its competitors.
Is PaxMedica's Equity-to-Asset too high?
PaxMedica's current Equity-to-Asset is -2.36.
How does PaxMedica's Equity-to-Asset compare to BTAX and NBIO?
PaxMedica's Equity-to-Asset of -2.36 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on PaxMedica and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PaxMedica's current Equity-to-Asset is -2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current Equity-to-Asset of -2.36. The current Equity-to-Asset is -2.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For PaxMedica (PXMD), the current Equity-to-Asset is -2.36 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMD has been successfully added to your 
